GLP-2 T (Tirzepatide)
Dual GIP/GLP-1 Agonist — Superior Weight Loss
Tirzepatide (GLP-2 T) is a dual GIP/GLP-1 receptor agonist showing up to 22.5% body weight reduction in trials — outperforming semaglutide in head-to-head data.
- Up to 22.5% body weight reduction — superior to semaglutide in head-to-head trials
- Dual GIP + GLP-1 receptor activation — two complementary appetite and metabolism mechanisms
- SURPASS-2: outperformed semaglutide at all doses tested
- Improved HbA1c reduction for metabolic health
- Reduces visceral fat more effectively than single-mechanism agents
COA verified · US domestic shipping
Tirzepatide (GLP-2 T): The Dual Agonist That Outperformed Semaglutide in Every Trial
22.5% Weight Reduction
SURMOUNT-1: maximum dose achieved 22.5% body weight reduction — the highest efficacy ever demonstrated in controlled weight loss trials at the time of publication.
Beat Semaglutide
SURPASS-2 head-to-head: tirzepatide outperformed semaglutide at all three doses tested — superior HbA1c and weight loss in direct comparison.
Dual Mechanism
GIP + GLP-1 dual agonism creates synergistic metabolic effects that neither receptor can achieve alone — explaining the superior clinical outcomes.
Visceral Fat Priority
Tirzepatide has shown preferential reduction of visceral adipose tissue — the metabolically dangerous fat that surrounds organs and drives inflammation.
The Science Behind GLP-2 T (Tirzepatide)
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. By activating both receptor types simultaneously, it achieves superior weight loss efficacy compared to GLP-1 agonists alone. Available commercially as Mounjaro (diabetes) and Zepbound (obesity).
▸Why Dual Agonism Is More Effective
GIP receptors and GLP-1 receptors have complementary but distinct mechanisms:
▸GIP (GIP receptor):
→Potentiates insulin secretion synergistically with GLP-1
→Reduces glucagon secretion
→Acts on adipose tissue to regulate fat storage
→Potential direct CNS appetite suppression
▸GLP-1 (GLP-1 receptor):
→Slows gastric emptying
→Reduces appetite via hypothalamic action
→Glucose-dependent insulin stimulation
Together, these mechanisms produce synergistic weight loss that exceeds GLP-1 agonism alone.
▸Clinical Superiority
SURMOUNT trials: Up to 22.5% body weight reduction at highest dose (15mg) over 72 weeks — significantly greater than semaglutide's ~15-16% in comparable populations.
In the SURPASS-2 trial directly comparing tirzepatide vs semaglutide, tirzepatide achieved superior weight loss at all doses tested.
Complete GLP-2 T (Tirzepatide) Benefits
- Up to 22.5% body weight reduction — superior to semaglutide in head-to-head trials
- Dual GIP + GLP-1 receptor activation — two complementary appetite and metabolism mechanisms
- SURPASS-2: outperformed semaglutide at all doses tested
- Improved HbA1c reduction for metabolic health
- Reduces visceral fat more effectively than single-mechanism agents
- Glucose-dependent insulin secretion — minimal hypoglycemia risk
- Beneficial effects on lipid profiles and cardiovascular markers
- Superior weight loss without proportional increase in side effects
GLP-2 T (Tirzepatide) Dosing Protocol
Escalation Protocol:
• Week 1-4: 2.5mg subcutaneous weekly
• Week 5-8: 5mg subcutaneous weekly
• Week 9-12: 7.5mg subcutaneous weekly
• Week 13-16: 10mg subcutaneous weekly
• Week 17+: 12.5-15mg (maximum dose, as tolerated)
Injection: Once weekly subcutaneous. Rotate sites.
All information on this site is for educational purposes only. Always consult with a qualified healthcare provider before use. COA documentation is available from Apollo Peptide Sciences for all products.
Get GLP-2 T (Tirzepatide)
Apollo Peptide Sciences — COA verified, US domestic, fast shipping.
Shop View Stack ProtocolsGLP receptor agonists work via hypothalamic appetite regulation and metabolic enhancement — proven in large-scale clinical trials.
All Weight Loss PeptidesStacks Best With
Stack GLP-2 T (Tirzepatide) With
Anti-AgingNAD+ 500mg
Cellular Energy & Longevity Cofactor
NAD+ is the master cellular energy molecule that declines 50% by age 50 — supplementation restores sirtuin activity, DNA repair, and mitochondrial function.
Weight LossGLP-1 S (Semaglutide)
Next-Gen GLP-1 Receptor Agonist for Weight Loss
Semaglutide (GLP-1 S) is a GLP-1 receptor agonist with clinical trials showing 15-20% body weight reduction — the most effective pharmacological weight loss agent studied.
Weight LossGLP-3 R (Retatrutide)
Triple Receptor Agonist — Next-Level Weight Loss
Retatrutide (GLP-3 R) is a triple GLP-1/GIP/glucagon receptor agonist showing 24% body weight reduction in Phase II — the most potent weight loss peptide in clinical development.